Medical/Pharmaceuticals

Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy

SUZHOU, China, May 22, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on...

2025-05-22 21:00 2220

MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany

HAMBURG, Germany, May 21, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences,  is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of t...

2025-05-22 10:38 2029

Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'

* Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD * Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive collaboration in Alzheimer's disease clinic...

2025-05-21 21:00 2788

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

* International recognition of quality system with GMP-compliance in the key markets ofBrazil, Indonesia, Egypt, Colombia and Argentina * Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory standards * Demonstrated BioDlink's cap...

2025-05-21 20:30 2215

China's Aphranel MagiCCrystal CaHA Filler Debuts Globally, Ushering in a New Era of Regenerative Aesthetic Medicine

SHANGHAI, May 21, 2025 /PRNewswire/ -- On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut at The Grand Halls inShanghai, a historic building on the Bund.    ...

2025-05-21 20:00 2843

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

* No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 toRussia * Company plans to export PCV13 vaccine components * "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently...

2025-05-21 20:00 2640

Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis

* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 * AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation * Efficacy and safety findings from this Phase 2 trial support advancing ...

2025-05-21 08:50 1741

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced ...

2025-05-20 21:02 2245

Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC

SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety a...

2025-05-20 18:18 3738

BioFlag Showcases Innovative Probiotic Solutions at Vitafoods Europe 2025

BARCELONA, Spain, May 20, 2025 /PRNewswire/ -- BIOFLAG CO.,LTD.(Bioflag), a leading probiotic enterprise located inChina, proudly unveiled its scientifically validated functional probiotic solutions at Vitafoods Europe 2025, drawing high attention from global media.

2025-05-20 18:00 1525

WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories

SHANGHAI, May 19, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- "Best CEO", "Bes...

2025-05-20 09:44 3135

United Imaging Emphasizes Differentiated Technology at ISMRM 2025

Among the highlights were a completely unique whole-body 8 ch-parallel transmit coil on the 5T uMR® Jupiter, and an FDA pending- 3T MRI that provides visualization of the body in motion. HOUSTON, May 19, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technol...

2025-05-20 00:00 2163

Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, ...

2025-05-19 21:00 2573

Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs

SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics....

2025-05-19 21:00 2176

Datasea Secures $100 Million in 5G+AI Contracts from Major Clients, Reinforcing Strategic Expansion and Long-Term Growth

The renewal from a key client demonstrates strong loyalty, while a new major deal reflects continued growth momentum heading into FY2026. BEIJING, May 19, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in acoustic high...

2025-05-19 20:30 2100

2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH

——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals("CureGene") ...

2025-05-17 08:41 4018

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment

TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will d...

2025-05-16 23:10 4456

Visionary: Pioneering a New Era in Cancer Screening

TORONTO, May 16, 2025 /PRNewswire/ -- Recently, Visionary has achieved a significant breakthrough in the field of early cancer screening and home self - testing technologies, attracting widespread attention from the industry. American Precision Biotech Inc. is a subsidiary of Visionary Holdings. ...

2025-05-16 21:30 2710

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...

2025-05-16 11:57 2203

Datasea Reports Third Fiscal Quarter 2025 Revenue of $10.4 Million Up 653.6% Year-over-Year

DTSS' AI-Powered Technology Serves as a Unifying Core Innovation for its 5G Multimodal Digital Platform and Acoustic High-Tech Segment BEIJING, May 15, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in 5G+AI multimodal ...

2025-05-15 21:30 4197
1 ... 40414243444546 ... 251

Week's Top Stories